We have received a communication from Oliver Jackson, Public Health Screening and Immunisation Manager for NHS England, advising that the Tripartite flu letter has finally been released and in a change this year, it is available by HTML only. NHSE are pushing for a PDF that will be easier for colleagues to share.
The letter can be found at the following link: www.gov.uk/government/publications/national-flu-immunisation-programme-plan
The letter outlines the cohorts eligible for vaccination this coming flu season. It is importance to highlight that the healthy 50-64yr cohort are no longer eligible. This was just a temporary extension during the pandemic. In addition, whilst the school age programme is confirmed for children of primary school age, it notes that a decision is yet to be made regarding the inclusion of children in secondary school years 7 to 11.
In terms of targets, Providers are expected to deliver a 100% offer to eligible groups. Providers should aim to equal or exceed last season’s (2022 to 2023) uptake particularly in clinical risk groups, children aged 2 and 3 years old, and pregnant women.
The Flu letter also details the vaccines which are reimbursable this year, please see below:
Reimbursable Adult Vaccines:
|Those aged 65 years and over||Those aged 18 to 64 years in eligible groups|
|Adjuvanted quadrivalent influenza vaccine (aQIV) / recombinant quadrivalent influenza vaccine (QIVr)
Cell-based quadrivalent influenza vaccine (QIVc) – only when every attempt to use aQIV or QIVr has been exhausted – evidence of this may be requested by the commissioner before reimbursement is agreed
|Cell-based quadrivalent influenza vaccine (QIVc) / recombinant quadrivalent influenza vaccine (QIVr)
Egg-grown quadrivalent influenza vaccine (QIVe) -only when every attempt to use QIVc or QIVr has been exhausted – evidence of this may be requested by the commissioner before reimbursement is agreed
Reimbursable Children’s Vaccines:
|Children aged 6 months to less than 2 years in clinical risk groups||Children aged 2 to less than 18 years in clinical risk groups; 2 to 3 years, and those in eligible school age cohorts|
|Cell-based quadrivalent influenza vaccine (QIVc), Seqirus (offered off-label)||Live attenuated influenza vaccine (LAIV), Fluenz® Tetra
Cell-based quadrivalent influenza vaccine (QIVc) where LAIV is contraindicated or otherwise unsuitable (for example parents object to LAIV on the grounds of its porcine gelatine content)
Should you have any questions, please feel free to contact any of the following addresses:
If you have a general screening query, please contact the team on email@example.com
If you have a general immunisation query, please contact the team on firstname.lastname@example.org